Safety profile consistent with other long-acting glucagon-like peptide 1 receptor agonists

Med-EatPlan plus extra virgin olive oil linked to lower risk for starting first glucose-lowering medication

Greater variability tied to higher risk, independent of mean levels for BMI, HDL cholesterol in childhood

Risk for diabetes increased for early menarche group; association partially mediated by adult BMI

Here are what the editors at HealthDay consider to be the most important developments in Diabetes & Endocrinology for July 2019. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.Oral Semaglutide …

Semaglutide has a safety and tolerability profile consistent with other GLP-1 receptor agonists

Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists

For two RPGs ≥115 mg/dL, sensitivity 87 percent and specificity 77 percent for predicting diabetes diagnosis

Statistically significant decreases in complication rates, but absolute decreases were low

Benefits on peripheral insulin sensitivity, disposition index for those at-risk or newly-diagnosed with T2DM